Minerva Neurosciences ( (NERV) ) has released its Q1 earnings. Here is a breakdown of the information Minerva Neurosciences presented to its investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system diseases, with a lead product candidate, roluperidone, aimed at treating negative symptoms in schizophrenia.
In its latest earnings report, Minerva Neurosciences reported a net loss of $3.8 million for the first quarter of 2025, a decrease from the $8.6 million loss in the same period last year. The company is navigating regulatory challenges, having received a Complete Response Letter from the FDA regarding its New Drug Application for roluperidone, which highlighted the need for additional studies to demonstrate the drug’s efficacy and safety.
Key financial metrics indicate that Minerva’s cash and cash equivalents have decreased to $17.3 million from $21.4 million at the end of 2024, reflecting ongoing operational expenses. The company’s stockholders’ deficit has widened to $29.1 million, driven by continued investment in research and development, although expenses in this area have decreased significantly compared to the previous year.
Looking forward, Minerva Neurosciences is focused on addressing the FDA’s concerns to advance roluperidone towards approval. The company is also exploring strategic options to secure additional funding to support its operations and future clinical trials, as it continues to face the challenges of maintaining its Nasdaq listing compliance.